Dr. Piet Ost presented “The Impact of Local Treatment of the Prostate in Patients with Newly Diagnosed Metastatic Prostate Cancer” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Keywords: metastatic prostate cancer, local treatment, ADT, clonal heterogeneity
How to cite: Ost, Piet. “The Impact of Local Treatment of the Prostate in Patients with Newly Diagnosed Metastatic Prostate Cancer” Grand Rounds in Urology. October 14-16, 2016. Accessed Nov 2024. https://dev.grandroundsinurology.com/bone-targeted-agents-metastatic-prostate-cancer-denosumab-bisphosphonates-radium-223
This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
ABOUT THE AUTHOR
Piet Ost, MD, PhD, is an Assistant Professor of Radiation Oncology and Adjunct Head of the Radiation Oncology Clinic at Ghent University, in East Flanders, Belgium. He is also Senior Clinical Investigator of the Research Foundation of Flanders. Dr. Ost is a member of the Immuno-Oncology Network of Ghent and has served as Vice-Chairman of the Young Academic Urologist Prostate Cancer Working Group of the European Association of Urology. He is a CRIG (Cancer Research Institute Ghent) group leader whose team focuses on urothelial cancers, particularly prostate cancer. Recently, Dr. Ost’s CRIG group has been investigating prognostic circulating biomarker panels and immunotherapies.
